Changeflow GovPing Pharma & Drug Safety Broad Institute Gene Editing Patent for SMA Tre...
Routine Notice Added Final

Broad Institute Gene Editing Patent for SMA Treatment

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260091141A1 by Broad Institute, Inc. covering gene editing methods, systems, and compositions for treating spinal muscular atrophy (SMA). The application (No. 19288071) was filed on August 1, 2025, and made publicly available on April 2, 2026. Inventors include David R. Liu, Mandana Arbab, and Zaneta Matuszek. The application covers modified messenger RNAs and delivery methods for treating microbial infections or improving subject health.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO published a patent application by Broad Institute disclosing gene editing compositions and methods for treating spinal muscular atrophy. The application claims modified messenger RNAs and delivery systems for introducing biological moieties into cells to reduce microorganism growth or improve subject health. CPC classifications include A61K 48/0066, C12N 9/226, C12N 15/11, and C12N 2310/20.

Patent application publications are informational notices establishing priority dates and public disclosure. They do not create immediate compliance obligations. Entities developing gene therapies or gene editing technologies should review the published claims to assess potential freedom-to-operate concerns. No response or action is required by filing date.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

GENE EDITING METHODS, SYSTEMS, AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY

Application US20260091141A1 Kind: A1 Apr 02, 2026

Assignee

The Broad Institute, Inc.

Inventors

David R. Liu, Mandana Arbab, Zaneta Matuszek

Abstract

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.

CPC Classifications

A61K 48/0066 C12N 9/226 C12N 15/11 C12N 2310/20

Filing Date

2025-08-01

Application No.

19288071

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091141A1
Docket
19288071

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Medical device makers
Industry sector
3254.1 Biotechnology 3254 Pharmaceutical Manufacturing
Activity scope
Biotechnology Patents Gene Therapy Patents
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!